Translational research
MDL is manifesting its international position in translational research by integrating clinical specimens and clinical studies with in vitro studies and molecular models of colon, bladder and prostate cancer diseases.

MDL aims at the establishment and maintainance of comprehensive tissue banks including detailed clinical follow-up in close cooperation with clinicians treating cancer patients.

Research aims
Molecular classification of patients in relation to disease stage, prognosis, outcome and treatment and the insight into pathways in subgroups of patients are desired. Bioinformatic modelling and databases help to understand the importance of our molecular findings. In 2003, a scientific milestone was set by our group by publishing a 32-gene molecular predictive classifier in bladder cancer (Dyrskjot,L. et al. Nat.Genet. 33(1): 90-96. 2003. PubMed).

Modern technology
MDL uses advanced techniques for in vitro studies including expression microarrays, SNP based and miRNA classification, investigation of genomic instability, functional classification of early molecular changes and pathways, and analysis of heterogenous and subhistological gene expression of laser microdissected tissues.

MDL has very modern laboratory facilities and computer equipment featuring Illumina next-generation sequencing (NGS), Affymetrix expression and exon arrays, Affymetrix 100K SNP array, miRNA and other custom arrays; Biomek robots; gridder; LightScanner, cell culture facilities and siRNA studies, laser microdissection (P.A.L.M.), cryo-microsections and immunohistochemistry; quantitive realtime PCR (ABI 7500 and ABI 7900HT FAST) and DNA sequencing (ABI 3130XL); and data analysis using database and array software (GeneSpring™, Ingenuity Pathway Analysis™, SDS 2.4).

Read about perspectives